Results 101 to 110 of about 4,268 (199)

Modelling the tail-phase pharmacokinetics of long-acting cabotegravir and rilpivirine from early pregnancy to postpartum at steady state. [PDF]

J Pharmacokinet Pharmacodyn
Atoyebi S, Waitt C, Olagunju A.
europepmc   +2 more sources

What does the scale‐up of long‐acting HIV pre‐exposure prophylaxis mean for the global hepatitis B epidemic?

Journal of the International AIDS Society
Introduction The HIV and hepatitis B virus (HBV) epidemics are interconnected with shared routes of transmission and specific antiviral drugs that are effective against both viruses. Nearly, 300 million people around the world live with chronic HBV, many
Amir M. Mohareb, Menan Gérard Kouamé, Marcellin Nouaman, Arthur Y. Kim, Joseph Larmarange, Anne M. Neilan, Karine Lacombe, Kenneth A. Freedberg, Anders Boyd, Patrick Coffie, Emily P. Hyle   +10 more
doaj   +1 more source

Cabotegravir/rilpivirine in pregnancy: early insights from clinical practice

Objective: To describe early experience with the use of cabotegravir/rilpivirine (CAB/RPV) in pregnancy and make recommendations based on these observations.
Jonathan B. Angel, Pierre Giguère, Michaeline McGuinty   +2 more
core   +1 more source

Satisfaction and Treatment Burden Among Early Adopters of Long-Acting Injectable Cabotegravir-Rilpivirine With and Without Viremia in Three US Ryan White Clinics. [PDF]

Open Forum Infect Dis
Christopoulos KA, Beckert A, McCracken C, Dance K, Plotkin S, Collins LF, McNulty MC, Hickey MD, Johnson MO, Mody A, Erguera XA, Koester KA, Liegeon G, Salazar J, Gutierrez J, Grochowski J, Dilworth SE, Neilands TB, Montgomery ET, Colasanti JA.   +19 more
europepmc   +1 more source

Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV

Modern ART is evolving, allowing the use of new drug formulations and alternative routes of administration to oral therapy. Long-acting (LA) cabotegravir and rilpivirine, the first fully injectable antiretroviral regimen approved for clinical use, is a ...
Rusconi, Stefano, Lo Caputo, Sergio, Gianotti, Nicola, Madeddu, Giordano, Cingolani, Antonella, Guaraldi, Giovanni, Marchetti, Giulia, Maggi, Paolo, Maggiolo, Franco, Di Biagio, Antonio, Bonora, Stefano, Nozza, Silvia, Taramasso, Lucia   +12 more
core   +1 more source

Sustained Virologic Suppression After Discontinuation of Long-acting Cabotegravir/Rilpivirine: A Two-case Series Highlighting Unexpected Heterogeneity in Pharmacokinetics and Viral Control. [PDF]

Open Forum Infect Dis
Marinosci A, Yerly S, Marzolini C, Calmy A.   +3 more
europepmc   +1 more source

Comparing carbon emissions from oral tenofovir disoproxil fumarate/emtricitabine for preexposure prophylaxis and long-acting injectables for HIV prevention. [PDF]

AIDS
Rodrigues K, Bahrambegi R, Reid M.
europepmc   +1 more source

Indirect Treatment Comparison of the Efficacy of Long-Acting Injectable Cabotegravir Compared With Lenacapavir for HIV Pre-exposure Prophylaxis. [PDF]

Adv Ther
Hawkins N, Hazra A, Brizzi M, Thompson J, Grove R, Sieverding M, Budnik P, Scherzer J, Danchenko N, Anderson SJ, Dupont-Benjamin L.   +10 more
europepmc   +1 more source

Chemoinformatic Approaches to Identify Bioactive Inhibitors Against Type I Dehydroquinase (DHQ1) Enzyme of Typhoidal <i>Salmonella</i>. [PDF]

Bioinform Biol Insights
Ashfaq A, Mariyam S, Aziz U, Mukhtar M, Andleeb S.   +4 more
europepmc   +1 more source

Corrigendum: Oral pre-exposure prophylaxis implementation in South Africa: a case study of USAID-supported programs

Frontiers in Reproductive Health
Jerome Wendoh Milimu, Lauren Parmley, Mahlodi Matjeng, Mathata Madibane, Mandisi Mabika, Jacques Livingston, Joseph Lawrence, Orapeleng Motlhaoleng, Hasina Subedar, Rethabile Tsekoa, Zandile Mthembu   +10 more
doaj   +3 more sources